Engineering Medicines To Improve Patient Care Pipeline Developing Best-In-Class Solutions for Patients Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Our pipeline represents a patient-centric model of innovation, which leverages proven biology and technology to efficiently allocate research and development resources, while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus. VRDN-001 VRDN-001 is a monoclonal antibody that binds and blocks the IGF-1R signaling pathway with sub-nanomolar affinity. This mechanism of action is clinically and commercially validated for the treatment of TED. The company’s ongoing first clinical trial for VRDN-001 is a Phase 1/2 proof of concept study that includes multiple randomized, placebo-controlled cohorts of TED patients designed to assess the potential for VRDN-001 to provide rapid improvement of signs and symptoms of TED, including proptosis. The protocol for this trial allows for additional patient cohorts to assess differing treatment paradigms that may offer advantages over currently available therapies, and mitigate patient treatment burden. The company expects to announce top line data from the proof-of-concept portion of the trial in the third quarter of 2022. Scientific publications for VRDN-001 can be found here. VRDN-002 VRDN-002 is a distinct IGF-1R monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of TED. In the first quarter of 2022, the Company is initiating a Phase 1 single ascending dose trial to explore safety, tolerability, pharmacokinetics, and target engagement of VRDN-002 in healthy volunteers. Data from the trial could demonstrate feasibility of a low-volume and/or low-frequency dosing paradigm and top-line data is expected to be announced by the third quarter of 2022. Scientific publications for VRDN-002 can be found here. VRDN-003 Viridian continues to explore opportunities to further advance therapeutics for TED. VRDN-004 VRDN-004 is a discovery-stage therapeutic antibody program for an undisclosed rare disease. We believe there is a significant opportunity to provide a more convenient, better performing product versus the only approved therapeutic in this disease. We are currently evaluating lead molecules generated by our antibody discovery and engineering platform. VRDN-005 VRDN-005 is a discovery-stage program for another undisclosed indication in which we believe patient care can be advanced with a new therapeutic monoclonal antibody. Read about our approach here.